Takeda gains FDA OK for potential insomnia blockbuster

Japan's Takeda has won FDA approval for Rozerem, a new sleep drug that will be the first prescription drug for insomnia not classified as a controlled substance. The approval is a coup for Takeda, positioning it to enter the fast-growing sleep drug category behind Sepracor's Lunesta. Neurocrine Bioscience and Merck are also each developing a new sleep drug, which they hope will compete for a growing, multibillion-dollar market that for years has been dominated by Ambien. A controlled-release form of Ambien is also in the works.

- read this report from Japan Today for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.